CN105158483A - Quantitative determination kit for hypersensitivity of Troponin I and detection method - Google Patents
Quantitative determination kit for hypersensitivity of Troponin I and detection method Download PDFInfo
- Publication number
- CN105158483A CN105158483A CN201510590529.8A CN201510590529A CN105158483A CN 105158483 A CN105158483 A CN 105158483A CN 201510590529 A CN201510590529 A CN 201510590529A CN 105158483 A CN105158483 A CN 105158483A
- Authority
- CN
- China
- Prior art keywords
- troponin
- monoclonal antibody
- magnetic particle
- human troponin
- combined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
Abstract
The invention relates to a quantitative determination kit for hypersensitivity of Troponin I and a detection method. The kit comprises magnetic micro particles the surfaces of which are combined with a first monoclonal antibody of anti-Troponin I, magnetic micro particles the surfaces of which are combined with a second monoclonal antibody of anti-Troponin I, enzyme-labeled third monoclonal antibody of anti-Troponin I and/or enzyme-labeled monoclonal fourth antibody of anti-Troponin I, wherein the first, second, third and fourth monoclonal antibodies are peculiarly different from different epitopes of Troponin I. The invention also provides a magnetic micro particle enzyme-catalyzed chemiluminiscence immunodetection method of Troponin I. According to the method, various types of different antibodies are adopted, an immune sandwich compound with magnetic micro particles-antibodies-antigen-enzyme-labeled antibody can be formed, and then Troponin I can be detected by a chemiluminiscence method. Compared with the prior art, the kit and the method have relatively high detection sensitivity and specificity.
Description
Technical field
The present invention relates to clinical examination field, especially relate to a kind of kit and the method for testing thereof that measure human troponin I (TroponinI) content.
Background technology
Human troponin by Troponin I, T, C tri-subunit form, by regulating the activity of calcium ion to striated muscle filamentous actin ATP enzyme to carry out modulate actin and myosin interacts together with tropomyosin.Troponin I (TnI) is striate a kind of key regulatory proteins.Although the function of all striated muscle TnI is all identical, myocardium TnI (cTnI, molecular mass 23.9kD) is obviously different from skeletal muscle TnI.
Because tissue specificity is high, cardiac muscle troponin I (cTnI) is the hypersensitivity mark of myocardial damage.CTnI also can be used for differentiating Skeletal muscle injury (as rhabdomyolysis, multiple injuries and non-cardiac surgery) and myocardial damage.CTnI has been clearly the prognostic marker of acute coronary syndrome (ACS) patient, can predict in the recent period, mid-term even long-term prognosis.
CTnI and cTnT has determined it is the best independent tag thing predicting ACS consequence.The sick association (ESC) of heart of Europe and ACC (ACC) combine and redefine myocardial infarction (MI).According to this definition, when Clinical Acute ischemic, when cTnI level in blood is higher than term of reference (healthy population) 99 percentile, MI can be diagnosed as.Require the imprecision (coefficient of variation)≤10% of troponin detection method simultaneously.According to above regulation, if a kind of detection method is under CV is less than the prerequisite of 10%, can measure 99% point of position or lower numerical value, we just can be referred to as super quick troponin.When applying the 99th percentile reference upper level, its critical value is 0.02ng/ml, and when CV≤10%, minimum measured value at least should be not more than 0.015ng/ml.
Redefining according to MI, has delivered many suggestions detecting the effect in ACS patient about cardiac troponin.In UAP and Non-ST Elevation Acute type myocardial infarction (NSTEMI) patient, the Serum Cardiac Troponin Level detected is relevant with high mortality.Therefore, the detection of troponin is very useful to the classification of risks of these patients, is also ACC/AHA (ACC) processes a directive/guide part to UAP and NSTEMI patient.CTn has the quite long diagnostic window phase (cTnI7 to 9 day, cTnT is longer), therefore detects that result is very important very soon.From detection angles, the method at present clinically for measuring cTnI mainly contains the method for exempting from of putting, colloidal gold immunity chromatography, ELISA method, chemoluminescence method etc.Chemoluminescence method detection time is short, highly sensitive, accuracy is high.
Magnetic particle enzyme-catalyzed chemical luminescence detection technique is a kind of is solid phase carrier of separating with magnetic particle, immune magnetic particle isolation technics is combined with enzyme linked immunosorbent detection technology and a kind of Novel immune detection method of setting up.Conventional ELISA method, the association reaction of antigen, antibody carries out on solid phase (elisa plate reacting hole) surface.Magnetic particle separation enzyme-linked immunoassay, the association reaction of antigen, antibody carries out under the condition of approximate liquid phase, and thus reaction fast, thoroughly.Have highly sensitive compared with traditional E LISA, detect the advantages such as the used time is few.
Summary of the invention
Therefore, according to the one side of the application, provide a kind of detection kit of Troponin I, it comprises: the magnetic particle being combined with the first anti-cTnI monoclonal antibody on the surface; Be combined with the magnetic particle of the second anti-cTnI monoclonal antibody on the surface; 3rd anti-cTnI monoclonal antibody of enzyme labeling; And/or the 4th of enzyme labeling the anti-cTnI monoclonal antibody, wherein said first, second, third and fourth monoclonal antibody is specific to the different epi-positions of human troponin I respectively.
In a particular embodiment, the first and second anti-cTnI monoclonal antibodies are covalently bond to the surface of magnetic particle.In a particular embodiment, the first and second anti-cTnI monoclonal antibodies can be incorporated on same magnetic particle, also can be bonded on different magnetic particles respectively.In a particular embodiment, the first and second anti-cTnI monoclonal antibodies are wrapped by magnetic particle independently of one another.
In the embodiment that some are concrete, alkaline phosphatase or horseradish peroxidase is adopted to mark anti-cTnI monoclonal antibody; The anti-cTnI monoclonal antibody of preferred employing alkali phosphatase enzyme mark third and fourth.
In the embodiment that some are concrete, the kit of the application also comprises the substrate of alkaline phosphatase or the substrate of horseradish peroxidase.Well known to a person skilled in the art that any suitable substrate is all allow; As nonrestrictive example, such as but not limited to dioxane, dioxane analog, luminol, Derivative of Luminol.
In some embodiments, the kit of the application also comprises cleansing solution, and described cleansing solution comprises Tris-HCl damping fluid and Tween 80.Preferably, cleansing solution contains Tween 80, NaCl, Proclin-300 and Tris-HCl damping fluid.In the embodiment that some are concrete, the concentration of described Tween 80 is 0.5g/L to 2g/L.In a preferred embodiment, the concentration of Tween 80 is 0.8g/L to 1g/L.
In some embodiments, the concentration of the first anti-cTnI monoclonal antibody in reagent is 3.2 μ g/ml; The concentration of the second anti-cTnI monoclonal antibody in reagent is 3.2 μ g/ml.
In some embodiments, the concentration of the 3rd anti-cTnI monoclonal antibody in reagent is 1.6 μ g/ml; The concentration of 4th anti-cTnI monoclonal antibody in reagent is 1.6 μ g/ml.
In some embodiments, the particle diameter of magnetic particle is 0.5 to 3.5 μm; Preferably 1 to 3 μm.
In some embodiments, the first and second anti-cTnI monoclonal antibodies are arranged in identical container.Third and fourth anti-cTnI monoclonal antibody is arranged in identical container.First and second anti-cTnI monoclonal antibodies are arranged in different containers from the third and fourth anti-cTnI monoclonal antibody.
In a particular embodiment, the kit of the application comprises or by forming as follows: (a) Magneto separate reagent, (b) enzyme labeling reagent and (c) substrate; Wherein Magneto separate pack is containing being combined with the magnetic particle of the first anti-cTnI monoclonal antibody on the surface and being combined with the magnetic particle of the second anti-cTnI monoclonal antibody on the surface; Described enzyme labeling pack is containing the 3rd anti-cTnI monoclonal antibody of enzyme labeling and the 4th anti-cTnI monoclonal antibody of enzyme labeling; Described substrate comprises luminol or derivatives thereof.
On the other hand, the application provides a kind of method improving the detection sensitivity of Troponin I, and it comprises the steps: that (a) will be combined with the magnetic particle of the first anti-cTnI monoclonal antibody on the surface and be combined with the magnetic particle mixing of the second anti-cTnI monoclonal antibody on the surface; And the 4th anti-cTnI monoclonal antibody of the 3rd of enzyme labeling the anti-cTnI monoclonal antibody and enzyme labeling mixes by (b); And optionally the potpourri of above-mentioned steps gained contacts with sample to be tested by (c); Wherein said first, second, third and fourth monoclonal antibody is specific to the different epi-positions of human troponin I respectively; Step (a) and step (b) order are interchangeable.
In a particular embodiment, be combined with the magnetic particle of the first anti-cTnI monoclonal antibody on the surface and be combined with the magnetic particle of the second anti-cTnI monoclonal antibody on the surface, mixing according to mass ratio 1:1.Be combined with the magnetic particle magnetic particle of the 3rd anti-cTnI monoclonal antibody and described surface being combined with the 4th anti-cTnI monoclonal antibody, mix according to mass ratio 1:1.
Another aspect, the application provides a kind of method preparing detection kit described in the application, and it comprises the steps: to be combined with the magnetic particle of the first anti-human Troponin I monoclonal antibody on the surface and to be combined with the magnetic particle mixing of the second anti-human Troponin I monoclonal antibody on the surface; And the 4th anti-human Troponin I monoclonal antibody of the 3rd of enzyme labeling the anti-human Troponin I monoclonal antibody and enzyme labeling is mixed, wherein said first, second, third and fourth monoclonal antibody is specific to the different epi-positions of human troponin I respectively.In a particular embodiment, be combined with the magnetic particle of the first anti-cTnI monoclonal antibody on the surface and be combined with the magnetic particle of the second anti-cTnI monoclonal antibody on the surface, mixing according to mass ratio 1:1.Be combined with the magnetic particle magnetic particle of the 3rd anti-cTnI monoclonal antibody and described surface being combined with the 4th anti-cTnI monoclonal antibody, mix according to mass ratio 1:1.
Accompanying drawing explanation
Fig. 1: the correlativity (unit of transverse and longitudinal coordinate is ng/ml, and horizontal ordinate is the measured value of contrast agent, and ordinate is the application's kit measured value) of the application's kit and contrast agent.
Embodiment
Embodiment
The preparation process of embodiment 1. Magneto separate reagent
One, the formulation operations step of reagent:
1, binding buffer liquid:
Take 21.32gMES add about 800ml pure water make it dissolve, later with NaOH adjust pH to 5.0, be settled to 1L.
2, cleaning fluid:
Take Tris3.025g, NaCl9g to add about 800ml pure water and make it to dissolve, adjust after pH to 7.2 with HCl later, after adding 0.5gTween-20 mixing, be settled to 1L.
3, cross-linking reagent:
Containing the ice-cold binding buffer liquid of 10mg/mlEDC, face with now joining.
4, confining liquid:
Biolipidure-203 or-206.
5, storage liquid:
Take Tris0.605g, NaCl0.9g to add about 80ml pure water and make it to dissolve, adjust after pH to 7.2 with HCl later, after adding 0.1gBSA, 0.1gTween-20 mixing, be settled to 100ml.
Two, the preparation process of Magneto separate reagent
1, after resuspended for magnetic particle EM1-100140 (Merck, particle diameter 0.93 μm also allow to use other commercially available equivalent magnetic particle, the product as Thermo), 1ml is got in 15ml centrifuge tube.
2, be placed on magnetic frame and carefully remove supernatant after Magneto separate 1min.
3, after adding the abundant resuspended magnetic particle of 10ml binding buffer liquid, be placed on magnetic frame and carefully remove supernatant after Magneto separate 1min, this step in triplicate.
4, after adding the abundant resuspended magnetic particle of 10ml binding buffer liquid, the mixing of 1ml cross-linking reagent is added, room temperature lucifuge mixing reaction 30min.
5, be placed on magnetic frame and carefully remove supernatant after Magneto separate 1min.
6, the cleaning of 10ml binding buffer liquid is added once, be placed on magnetic frame and carefully remove supernatant after Magneto separate 1min, the anti-cTnI monoclonal antibody of 1.5mg first (purchased from Hytest, article No. 916) mixing is added, room temperature lucifuge mixing reaction 3h after adding 10ml binding buffer liquid.
7, add 10ml cleaning fluid cleaning magnetic particle 3 times, add the mixing of 5ml confining liquid after removing supernatant for the last time, room temperature lucifuge mixing reaction is spent the night.
8, add 10ml cleaning fluid and clean three times.
9, the rear 4 DEG C of storages of 10ml storage liquid mixing are added.
Second anti-cTnI monoclonal antibody (purchased from Hytest, article No. 3C7) wraps quilt equally according to above-mentioned steps 1 to 9.
Embodiment 2. enzymic-labelled antibody preparation process
One, the configuration step of reagent:
1、0.1MPBSpH7.4：
Take KH
2pO
42.4g, Na
2hPO
414.4g, NaCl8g, KCl0.2g adjust pH to 7.4, are settled to 1L after adding the dissolving of 800ml pure water.
2, storage liquid:
Take Tris0.605g to add about 80ml pure water and make it to dissolve, adjust after pH to 7.4 with HCl later and add 2gBSA, 0.02gMgCl
2and 0.02gNaN
3, after mixing, be settled to 100ml.
Two, enzymic-labelled antibody step;
1, get the anti-cTnI monoclonal antibody of 2mg the 3rd (purchased from Hytest, article No. 560) to be carefully added to respectively in bag filter with 2mg alkaline phosphatase, dialyse 2h in 0.1MPBSpH7.4.
2, take out the antibody of dialyse and alkaline phosphatase as in centrifuge tube, slowly add 0.2ml0.1% glutaraldehyde, room temperature lucifuge reacts 2h.
3,0.1ml monoethanolamine is slowly added, room temperature lucifuge reaction 1h.
4th anti-cTnI monoclonal antibody (purchased from Hytest, article No. MF4) carries out same mark according to above-mentioned steps 1 to 3.
Three, enzymic-labelled antibody purification step;
1, desalination:
Take 20mMPBS as eluent, flow velocity 5ml/min, 5ml desalting column, loading speed 2ml/min; First use 20mMPBS rinse-system 30min, loading is also collected.This step operation object is to remove unnecessary glutaraldehyde and monoethanolamine.
2, purifying:
Take 20mMPBS as the HPLC prepacked column of mobile phase, flow velocity 0.5ml/min, TSK3000; First by anti-cTnI monoclonal antibody and alkaline phosphatase loading respectively, the appearance time of reporter antibody and alkaline phosphatase; Afterwards by the antibody loading of alkaline phosphatase mark; The peak position of unconjugated antibody and alkaline phosphatase is judged, the antibody of what remaining peak area was larger is then alkali phosphatase enzyme mark according to appearance time; The appearance time of the good each component of record, finally by the antibody loading of alkali phosphatase enzyme mark, collects sample according to appearance time before; Each peak is collected in a centrifuge tube.To be added in storage liquid after the component ultrafiltration concentration of each collection, 4 DEG C of preservations.
Embodiment 3. dilution configures
This dilution is antibody diluent, is used for antibody dilution to working concentration.
Take HEPES11.9g, bovine serum albumin(BSA) 7.0g, Tween 80 3.3g, NaCl9g, HBR1g, lowlenthal serum 5ml, rat immune globulin G0.5g, NaN
31g is in 1L beaker; Add 500ml purified water to make it to dissolve completely; Carefully add 0.5mlPC300; 1L is settled to after all dissolving completely.
Embodiment 4. cleansing solution configuration step:
Take Tris6.057g in 1L beaker, add 800ml purified water and make it to dissolve completely, with hydrochloric acid, pH is adjusted to 7.2, adds NaCl6g, Tween-801g, NaN
31L is settled to after 1g makes it to dissolve completely.
Test case 1. sensitivity:
1, get 50 μ l anti-cTnI monoclonal antibody standard items (purchased from Fitzgerald, article No. 30-1362) and sample to be tested (serum) to add bottom corresponding reaction cup.
2, respectively get 40 μ l and be coated with the Magneto separate reagent of first antibody and the Magneto separate reagent of second antibody in each reaction cup.
3, the enzyme labeling reagent of the enzyme labeling reagent and the 4th antibody that 40 μ l are coated with the 3rd antibody is respectively got in each reaction cup.
4, the reagent mixing will added gently, 37 DEG C of temperature bath 15min.
5, test tube is placed in magnetic separator, Magneto separate.Add 300 μ l cleansing solutions, Magneto separate, repeated washing is separated 5 times.
6, accurately add in 100 μ l alkaline phosphatase substrates to test tube and mix 40 seconds, put into luminometer and detect.
Sensitivity results:
Zero point is repeated 20 times simultaneously, and getting its mean value is 924, adds 2SD and typical curve and compares that to calculate result be 0.015ng/ml.
Test case 2. correlativity
1, contrast agent:
Contrast agent is ratified the ripe kit of listing by Drug Administration department.Its reaction principle is sandwich method.The kit composition of contrast agent: reagent 1 is the magnetic-particle of coated antibody, and reagent 2 is acridinium ester label antibody.
2, comparative approach:
The kit of the application is consistent with the Cleaning Principle of contrast agent box; Adopt hospital collect serum altogether 83 parts carry out parallel testing; Standard items are as described in test case 1.
3, experimental result:
The measured value (unit is ng/ml) of table 1. the application kit and contrast agent
The correlativity of the application's kit and contrast reality of having gone on the market is expressed as: Y=0.9425X+0.1058, R
2=0.9897.This shows, the kit of the application and commercially available prod have good correlativity (Fig. 1).
But be also not difficult to find out from above-mentioned data, in the test result of contrast agent, part serum measured value is much on the low side, and what have even occurs that patient is diagnosed as Healthy People, there is undetected problem.
The comparison of test case 3. two kinds of antibody and the kit prepared by four kinds of antibody
Only adopt two kinds of antibody (any 2 in above-mentioned 4 antibody of the application, for first antibody and the 3rd antibody), be prepared into kit according to above-mentioned same method, and the kit that the application comprises 4 antibody compares.Relatively data are as follows:
The comparison (unit is ng/ml) of table 2. two kinds of antibody and the kit prepared by four kinds of antibody
Be not difficult to find out from above-mentioned data, when only adopting two kinds of antibody to prepare kit, the part serum measured value obtained is on the low side, and what have even occurs that patient is judged as healthy individuals, there is undetected problem.Above-mentioned data illustrate, adopting four kinds of antibody to prepare kit can significantly improve undetected problem, greatly reduces false-negative appearance.
Claims (11)
1. a detection kit for Troponin I, it comprises:
Be combined with the magnetic particle of the first anti-human Troponin I monoclonal antibody on the surface;
Be combined with the magnetic particle of the second anti-human Troponin I monoclonal antibody on the surface; And
3rd anti-human Troponin I monoclonal antibody of enzyme labeling and/or the 4th anti-human Troponin I monoclonal antibody of enzyme labeling,
Wherein said first, second, third and fourth monoclonal antibody is specific to the different epi-positions of human troponin I respectively.
2. the detection kit of Troponin I according to claim 1, wherein said first and second anti-human Troponin I monoclonal antibodies are covalently bond to the surface of described magnetic particle.
3. the detection kit of the Troponin I according to any one of claim 1-2, wherein said enzyme is selected from following one: alkaline phosphatase and horseradish peroxidase.
4. the detection kit of the Troponin I according to any one of claim 1-3, it also comprises the substrate of alkaline phosphatase or the substrate of horseradish peroxidase,
Preferred described substrate is selected from: dioxane, dioxane analog, luminol and Derivative of Luminol.
5. the detection kit of the Troponin I according to any one of claim 1-4, it also comprises cleansing solution, and described cleansing solution comprises Tris-HCl damping fluid and Tween 80;
Preferably, the concentration of described Tween 80 is 0.5g/L to 2g/L, is more preferably 0.8g/L to 1g/L;
More preferably, described cleansing solution contains 6.057g/LTris, 6g/LNaCl, 1g/L Tween 80,1g/LNaN
3, pH is adjusted to 7.2 by HCl.
6. the detection kit of the Troponin I according to any one of claim 1-5, wherein:
Tris-HCl, NaCl, BSA and Tween-20 is also comprised in described Magneto separate reagent;
Preferably, in Magneto separate reagent, also comprise 6.05g/LTris, 9g/LNaCl, 1g/LBSA and 1g/L Tween-20, adjust pH to 7.2 with HCl; Also Tris-HCl, BSA, MgCl is comprised in described enzyme labeling reagent
2and NaN
3,
Preferably, also 6.05g/LTris, 20g/LBSA, 0.2g/LMgCl is comprised in described enzyme labeling reagent
2and 0.2g/LNaN
3, adjust pH to 7.4 with HCl.
7. the detection kit of the Troponin I according to any one of claim 1-6, it comprises or by forming as follows:
Magneto separate reagent, enzyme labeling reagent and substrate;
Wherein said Magneto separate pack contains: the magnetic particle being combined with the first anti-human Troponin I monoclonal antibody on the surface, and the magnetic particle being combined with the second anti-human Troponin I monoclonal antibody on the surface;
Wherein said enzyme labeling pack contains: the 3rd anti-human Troponin I monoclonal antibody, and the 4th anti-human Troponin I monoclonal antibody;
Wherein said substrate comprises: luminol or derivatives thereof,
The particle diameter of wherein said magnetic particle is 0.5 to 3.5 μm; Preferably 1 to 3 μm.
8. improve a method for the detection sensitivity of Troponin I, it comprises the steps:
To the magnetic particle of the first anti-human Troponin I monoclonal antibody be combined with on the surface and be combined with the magnetic particle mixing of the second anti-human Troponin I monoclonal antibody on the surface; And
4th anti-human Troponin I monoclonal antibody of the 3rd of enzyme labeling the anti-human Troponin I monoclonal antibody and enzyme labeling is mixed,
Wherein said first, second, third and fourth monoclonal antibody is specific to the different epi-positions of human troponin I respectively.
9. method according to claim 8, wherein:
Described be combined with the first anti-human Troponin I monoclonal antibody magnetic particle and described surface on be combined with the magnetic particle of the second anti-human Troponin I monoclonal antibody, mix according to mass ratio 1:1;
Described be combined with the 3rd anti-human Troponin I monoclonal antibody magnetic particle and described surface on be combined with the magnetic particle of the 4th anti-human Troponin I monoclonal antibody, mix according to mass ratio 1:1.
10. method according to claim 9, wherein:
The concentration of the first and second anti-human Troponin I monoclonal antibodies is 3.2 μ g/ml respectively; The concentration of described third and fourth anti-human Troponin I monoclonal antibody is 1.6 μ g/ml respectively.
11. 1 kinds of methods preparing the detection kit of the Troponin I described in any one of claim 1-7, method comprises:
To the magnetic particle of the first anti-human Troponin I monoclonal antibody be combined with on the surface and be combined with the magnetic particle mixing of the second anti-human Troponin I monoclonal antibody on the surface; And
4th anti-human Troponin I monoclonal antibody of the 3rd of enzyme labeling the anti-human Troponin I monoclonal antibody and enzyme labeling is mixed,
Wherein said first, second, third and fourth monoclonal antibody is specific to the different epi-positions of human troponin I respectively.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510590529.8A CN105158483A (en) | 2015-09-16 | 2015-09-16 | Quantitative determination kit for hypersensitivity of Troponin I and detection method |
| CN201811196195.6A CN109580954B (en) | 2015-09-16 | 2015-09-16 | Hypersensitivity quantitative determination kit for human troponin I and detection method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510590529.8A CN105158483A (en) | 2015-09-16 | 2015-09-16 | Quantitative determination kit for hypersensitivity of Troponin I and detection method |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811196195.6A Division CN109580954B (en) | 2015-09-16 | 2015-09-16 | Hypersensitivity quantitative determination kit for human troponin I and detection method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105158483A true CN105158483A (en) | 2015-12-16 |
Family
ID=54799404
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510590529.8A Pending CN105158483A (en) | 2015-09-16 | 2015-09-16 | Quantitative determination kit for hypersensitivity of Troponin I and detection method |
| CN201811196195.6A Active CN109580954B (en) | 2015-09-16 | 2015-09-16 | Hypersensitivity quantitative determination kit for human troponin I and detection method thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811196195.6A Active CN109580954B (en) | 2015-09-16 | 2015-09-16 | Hypersensitivity quantitative determination kit for human troponin I and detection method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105158483A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106366199A (en) * | 2016-08-31 | 2017-02-01 | 上海科华生物工程股份有限公司 | Troponin I monoclonal antibody magnetic particles and preparation method thereof, and detection kit |
| CN109061189A (en) * | 2018-08-17 | 2018-12-21 | 深圳天辰医疗科技有限公司 | A kind of Troponin I detection kit and preparation method thereof |
| CN109613242A (en) * | 2018-11-01 | 2019-04-12 | 深圳天辰医疗科技有限公司 | A kind of creatine kinase isozyme detection kit and preparation method thereof |
| CN109709323A (en) * | 2019-02-15 | 2019-05-03 | 深圳上泰生物工程有限公司 | High quick cardiac muscle troponin I magnetic microparticle chemiluminescence immunity detection reagent, Preparation method and use |
| CN110161250A (en) * | 2018-02-11 | 2019-08-23 | 博阳生物科技（上海）有限公司 | A kind of homogeneous human cardiac troponin I quick detection kit, system, detection method and application |
| CN110554198A (en) * | 2019-09-18 | 2019-12-10 | 潍坊市康华生物技术有限公司 | Troponin I detection test method |
| CN111308085A (en) * | 2019-12-30 | 2020-06-19 | 菲鹏生物股份有限公司 | Detection method and kit for hypersensitive cardiac troponin I |
| CN111735965A (en) * | 2020-07-02 | 2020-10-02 | 北京美联泰科生物技术有限公司 | Cardiac troponin I detection reagent, preparation method thereof and cardiac troponin I detection kit |
| CN112526140A (en) * | 2020-11-16 | 2021-03-19 | 北京利德曼生化股份有限公司 | Magnetic particle chemiluminescence detection kit for determining content of hypersensitive troponin T |
| CN114544978A (en) * | 2022-03-04 | 2022-05-27 | 美康生物科技股份有限公司 | IGF-1 detection kit, preparation method and detection method thereof |
| CN117054670A (en) * | 2023-10-12 | 2023-11-14 | 北京豪迈生物工程股份有限公司 | Kit for determining content of melanoma glycoprotein B and preparation method thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113125742B (en) * | 2019-12-30 | 2022-12-27 | 广东唯实生物技术有限公司 | Detection method and kit for hypersensitive cardiac troponin I |
| CN112964885B (en) * | 2021-02-20 | 2022-11-11 | 广东菲鹏生物有限公司 | Amino-terminal brain natriuretic peptide detection method and kit |
| CN114280307A (en) * | 2021-11-08 | 2022-04-05 | 宏葵生物（中国）股份有限公司 | Nano magnetic particle chemiluminescence detection kit for hypersensitive cardiac troponin I and preparation method and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101226200A (en) * | 2007-01-19 | 2008-07-23 | 天津天美生物技术有限公司 | Chemiluminescence immunity analysis detecting myocardium calcium protein T hypersensitization method for acridine ester and alkaline phosphatase |
| US20110129854A1 (en) * | 2009-12-02 | 2011-06-02 | Abbott Laboratories | Assay for diagnosis of cardiac myocyte damage |
| CN102426246A (en) * | 2011-08-31 | 2012-04-25 | 内蒙古科慧生物科技有限责任公司 | Human troponin I quantitative determination kit and detection method |
| CN102565037A (en) * | 2012-01-11 | 2012-07-11 | 郑州安图绿科生物工程有限公司 | Magnetic particle chemiluminescence kit for quantitatively detecting plasma rennin |
| CN102597774A (en) * | 2009-09-23 | 2012-07-18 | 皇家飞利浦电子股份有限公司 | Binding assay with multiple magnetically labelled tracer binding agents |
| CN103649755A (en) * | 2011-05-27 | 2014-03-19 | 雅培医护站股份有限公司 | TSH immunoassays and processes for performing TSH immunoassays in the presence of endogenous contaminants in restricted wash formats |
| CN104781278A (en) * | 2012-07-03 | 2015-07-15 | 华盛顿大学 | Antibodies to TAU |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101368961B (en) * | 2008-04-02 | 2012-11-14 | 北京科美生物技术有限公司 | Chemical luminescence immune analysis quantitative measuring reagent kit for urine bladder cancer antigen and preparation method thereof |
| CN102735848A (en) * | 2012-07-05 | 2012-10-17 | 北京源德生物医学工程有限公司 | Enzymatic chemiluminescence immunodetection method and reagent kit for human troponin I |
-
2015
- 2015-09-16 CN CN201510590529.8A patent/CN105158483A/en active Pending
- 2015-09-16 CN CN201811196195.6A patent/CN109580954B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101226200A (en) * | 2007-01-19 | 2008-07-23 | 天津天美生物技术有限公司 | Chemiluminescence immunity analysis detecting myocardium calcium protein T hypersensitization method for acridine ester and alkaline phosphatase |
| CN102597774A (en) * | 2009-09-23 | 2012-07-18 | 皇家飞利浦电子股份有限公司 | Binding assay with multiple magnetically labelled tracer binding agents |
| US20110129854A1 (en) * | 2009-12-02 | 2011-06-02 | Abbott Laboratories | Assay for diagnosis of cardiac myocyte damage |
| CN103649755A (en) * | 2011-05-27 | 2014-03-19 | 雅培医护站股份有限公司 | TSH immunoassays and processes for performing TSH immunoassays in the presence of endogenous contaminants in restricted wash formats |
| CN102426246A (en) * | 2011-08-31 | 2012-04-25 | 内蒙古科慧生物科技有限责任公司 | Human troponin I quantitative determination kit and detection method |
| CN102565037A (en) * | 2012-01-11 | 2012-07-11 | 郑州安图绿科生物工程有限公司 | Magnetic particle chemiluminescence kit for quantitatively detecting plasma rennin |
| CN104781278A (en) * | 2012-07-03 | 2015-07-15 | 华盛顿大学 | Antibodies to TAU |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106366199B (en) * | 2016-08-31 | 2020-03-24 | 上海科华生物工程股份有限公司 | Troponin I monoclonal antibody magnetic particle, preparation method thereof and detection kit |
| CN106366199A (en) * | 2016-08-31 | 2017-02-01 | 上海科华生物工程股份有限公司 | Troponin I monoclonal antibody magnetic particles and preparation method thereof, and detection kit |
| CN110161250A (en) * | 2018-02-11 | 2019-08-23 | 博阳生物科技（上海）有限公司 | A kind of homogeneous human cardiac troponin I quick detection kit, system, detection method and application |
| CN109061189A (en) * | 2018-08-17 | 2018-12-21 | 深圳天辰医疗科技有限公司 | A kind of Troponin I detection kit and preparation method thereof |
| CN109613242A (en) * | 2018-11-01 | 2019-04-12 | 深圳天辰医疗科技有限公司 | A kind of creatine kinase isozyme detection kit and preparation method thereof |
| CN109709323A (en) * | 2019-02-15 | 2019-05-03 | 深圳上泰生物工程有限公司 | High quick cardiac muscle troponin I magnetic microparticle chemiluminescence immunity detection reagent, Preparation method and use |
| CN110554198A (en) * | 2019-09-18 | 2019-12-10 | 潍坊市康华生物技术有限公司 | Troponin I detection test method |
| CN111308085A (en) * | 2019-12-30 | 2020-06-19 | 菲鹏生物股份有限公司 | Detection method and kit for hypersensitive cardiac troponin I |
| CN111308085B (en) * | 2019-12-30 | 2021-02-23 | 菲鹏生物股份有限公司 | Detection method and kit for hypersensitive cardiac troponin I |
| CN111735965A (en) * | 2020-07-02 | 2020-10-02 | 北京美联泰科生物技术有限公司 | Cardiac troponin I detection reagent, preparation method thereof and cardiac troponin I detection kit |
| CN111735965B (en) * | 2020-07-02 | 2023-07-25 | 北京美联泰科生物技术有限公司 | Myocardial troponin I detection reagent, preparation method and myocardial troponin I detection kit |
| CN112526140A (en) * | 2020-11-16 | 2021-03-19 | 北京利德曼生化股份有限公司 | Magnetic particle chemiluminescence detection kit for determining content of hypersensitive troponin T |
| CN114544978A (en) * | 2022-03-04 | 2022-05-27 | 美康生物科技股份有限公司 | IGF-1 detection kit, preparation method and detection method thereof |
| CN117054670A (en) * | 2023-10-12 | 2023-11-14 | 北京豪迈生物工程股份有限公司 | Kit for determining content of melanoma glycoprotein B and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109580954A (en) | 2019-04-05 |
| CN109580954B (en) | 2022-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105158483A (en) | Quantitative determination kit for hypersensitivity of Troponin I and detection method | |
| US10472400B2 (en) | Cardiac troponin I ultra-sensitive detection reagent kit, and ultra-sensitive detection method therefor | |
| CN104714015B (en) | Detection kit and detection method for heart-type fatty acid binding protein | |
| CN104714025B (en) | NT-proBNP detection kit and detection method | |
| CN104634980A (en) | Cardiac troponin I (cTn I) hypersensitive detection kit and hypersensitive detection method | |
| CN109709323A (en) | High quick cardiac muscle troponin I magnetic microparticle chemiluminescence immunity detection reagent, Preparation method and use | |
| JP3586243B2 (en) | Highly sensitive immunoassay | |
| EP2631649A1 (en) | Method and device for the rapid diagnosis of diseases in faecal samples | |
| WO2011012053A1 (en) | Test strip for detecting anti-cyclic citrullinated peptide antibody in blood and method of preparing the same | |
| CN108445222A (en) | A kind of kit and preparation method quantitatively detecting cardic fatty acid binding protein | |
| CN109765382A (en) | A kind of latex enhancing immune of serum cardiac troponin T is than turbid detection kit | |
| JP2014081365A (en) | Method for measuring antibody with protein on cell surface as antigen | |
| EP3243076B1 (en) | Methods for detecting a marker for active tuberculosis | |
| JP2002202310A (en) | Substance detecting reagent and substance detecting method | |
| CN106198997B (en) | A kind of kit of Quantitative detection troponin and creatine kinase isozyme | |
| JP2023017986A (en) | Direct immunoassay measurement of autoantibodies | |
| JPH08509806A (en) | Methods and assays | |
| WO2017083599A1 (en) | Platelet biomarkers and diagnostic methods for vascular diseases | |
| JP6088501B2 (en) | Method for obtaining a conjugate to preprovasopressin or a fragment thereof | |
| CN108152486A (en) | The magnetic microparticle chemiluminescence detection kit and preparation method of a kind of human soluble ST2 | |
| CN101368972A (en) | Chemical luminescence immune assay determination reagent kit for hydrocortisone and preparation method thereof | |
| JP4029298B2 (en) | Method for removing sticky microvesicles | |
| WO2017091487A1 (en) | Kits for detection of hepcidin | |
| NL2016301B1 (en) | Method for detecting a marker for active tuberculosis. | |
| CN102183657A (en) | Method for greatly improving chemiluminescence magnetic enzyme immunization sensitivity by depending on polystyrene nanoparticles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151216 |
|
| RJ01 | Rejection of invention patent application after publication |